Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GABRINOX vs FOLFIRINOX in first-line metastatic pancreatic cancer
2021-001353-31Phase 2Active
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of gemcitabine, paclitaxel and FOLFIRINOX in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Institut du Cancer de Montpellier. Primary endpoint: Progression-free survival. Started Jun 2021; status: active.
02
Drugs
gemcitabinepaclitaxelFOLFIRINOX
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2021-001353-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001353-31.